Increase in stress contributes to impaired jaw function in juvenile idiopathic arthritis: a two-year prospective study

Table 2 Demographic data, disease activity and temporomandibular disorder diagnoses for 40 patients with juvenile idiopathic arthritis at baseline and 40 patients at two year follow- up

			BASELINE					TWO-YEAR FOLLOW UP
			Percentiles					Percentiles
		Median	25th	75th	% pos	n	Median	25th	75th	% pos	n
Individuals
Age	years	12	9	14		40	14	12	16		40
Sex	boys/girls					10/30					10/30
Age at diagnosis	years	9	4	11		40	9	4	11		40
Disease duration	years	4	2	7		40	6	3	8		40
Disease activity
JADAS71	0-101	6.2	3.1	9.9		40	3.0	0.5	8.5		40
Erythrocyte sedimentation rate^a	mm	7	4	10	8	39	0	0	0	0	39
C-reactive protein^a	mg/L	0	0	0	5	39	0	0	0	3	39
Rheumatoid factor	IU/mL	0	0	0	7	39	0	0	0	8	39
Anti-citrullinated antibodies	U/mL	0	0	0	10	40	0	0	0	10	40
Antinuclear antibodies					35	40				35	40
HLA-B27 pos					12	40				12	40
Medication
NSAID					60%	24				43%	17
DMARD					63%	25				38%	15
Glucocorticoids					15%	6				7%	3
Biologics					27%	11				35%	14
Biologics and DMARD					13%	5				15%	6
No medication					10%	4				17%	8
DC/TMD diagnoses
Myalgia	n					8					10
Myofascial pain with referral	n					2					1
Arthralgia	n (joints)					7					11
Headache attributed to TMD	n					3					1
Combinations from above
Myalgia and arthralgia	n					2					6
Myalgia, arthralgia and headache	n					2					1

n number of observations, JADAS71 71-joint Juvenile Arthritis Disease Activity Score, DC/TMD Diagnostic criteria for temporomandibular disorders. NSAID Non-steroidal anti-inflammatory drug, DMARD Disease-modifying anti-rheumatic drugs (Methotrexate, Plaquenil, Orencia, Salazopyrin), Glucocorticoids (Prednisolone) Biologics at baseline (Adalimumab (4), Etanercept (5), Abatacept (1) and Golimumab (1)) and for 2-year follow up (Adalimumab (7), Etanercept (2), Tocilizumab (3) and Infliximab (1))
^aNormal values for ESR (<30 mm/h), CCP (<7 U/mL) and CRP (<5 mg/L) were counted as 0. Other subtypes of JIA (systemic arthritis, psoriatic arthritis, enthesitis-related or undifferentiated arthritis)

ISSN: 1546-0096